Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Christopher Bell
- Target Recruit Count
- 37
- Registration Number
- NCT02371187
- Locations
- 🇺🇸
Colorado State University, Dept. of Health and Exercise Science, Fort Collins, Colorado, United States
Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT02338921
- Locations
- 🇰🇷
Soo Lim, Seongnam, Gyeonggi, Korea, Republic of
The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- University of Padova
- Target Recruit Count
- 33
- Registration Number
- NCT02327039
- Locations
- 🇮🇹
Division of Metabolic Diseases, University Hospital of Padova, Padova, Italy
Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- Kinderkrankenhaus auf der Bult
- Target Recruit Count
- 36
- Registration Number
- NCT02325206
- Locations
- 🇩🇪
Kinder - und Jugendkrankenhaus AUF DER BULT, Hannover, Germany
Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Uppsala University
- Target Recruit Count
- 50
- Registration Number
- NCT02313220
- Locations
- 🇸🇪
Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University and Section for Diabetes and Endocrinology at the Uppsala University Hospital, Uppsala, Sweden
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 461
- Registration Number
- NCT02284893
- Locations
- 🇿🇦
Research Site, Soweto, South Africa
A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 223
- Registration Number
- NCT02279407
- Locations
- 🇸🇪
Research Site, Örebro, Sweden
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 833
- Registration Number
- NCT02268214
- Locations
- 🇬🇧
Research Site, Welwyn Garden City, United Kingdom
Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Slotervaart Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT02253121
- Locations
- 🇳🇱
Slotervaart Hospital, Amsterdam, Netherlands
🇳🇱Spaarne Ziekenhuis, Hoofddorp, Netherlands
🇳🇱OLVG West, Amsterdam, Netherlands
Dapagliflozin Effects on Epicardial Fat
- Conditions
- Interventions
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 100
- Registration Number
- NCT02235298
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.